Clinical trials: Thoracic
Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries
Multicenter, single-arm retrospective and prospective registry is being conducted to confirm the clinical performance and safety of GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis when used as a Bridging Stent with Branched…
- Trial name
- EMBRACE (NCT05143138)
- Testing
- GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
- Where
- 14 sites in Denmark, Italy and 4 more
- Volunteers
- 259 people
- Sponsor
- W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta, Lesion
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1
The objective of this study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta.
- Trial name
- SSB 11-02 (NCT02777528)
- Testing
- GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
- Where
- 39 sites in United States, Japan
- Volunteers
- 79 people
- Sponsor
- W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta; Lesion
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
The objective of this study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta, requiring Zone 2 proximal implantation…
- Trial name
- SSB 11-02 (NCT02777593)
- Testing
- GORE® TAG® Thoracic Branch Endoprosthesis
- Where
- 35 sites in United States
- Volunteers
- 250 people
- Sponsor
- W.L.Gore & Associates
Lung Diseases, Carcinoma, Non-Small-Cell Lung
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment…
- Conditions
- Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- APOLO (NCT04776447)
- Testing
- Carboplatin, Placlitaxel, Atezolizumab
- Where
- 22 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundación GECP
Thoracic Surgery, Cardiopulmonary Bypass
Cerebral Autoregulation Monitoring During Cardiac Surgery
Neurological complications from cardiac surgery are an important source of operative mortality, prolonged hospitalization, health care expenditure, and impaired quality of life.
- Trial name
- NCT00981474
- Testing
- blood pressure maintenance based on cerebral blood flow autoregulation measurement, Control group
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Northwestern University
Anesthesia, Nerve Block
Comparison of the Effect of Preoperative and Postoperative ESP and PVB on Postoperative Pain in VATS
The aim of this prospective controlled randomised clinical trial was to identify the analgesic method that is more effective than two different regional analgesia techniques routinely used for pain control after video-assisted…
- Conditions
- Anesthesia, Nerve Block, Pain, Postoperative, Thoracic Surgery, Video Assisted
- Trial name
- NCT06488014
- Testing
- Erector spina plan block (ESP), Paravertebral block
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Ankara University
Thoracic Tumours
Pembrolizumab and Palliative Radiotherapy in Lung
Lung cancer is the second most common cancer in the UK with around 43,500 new patients diagnosed each year. About 69% of patients are diagnosed with advanced stage disease and at present these patients would be expected to…
- Trial name
- PEAR (NCT02587455)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Older Adults, Anxiety
Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery
Using a Hybrid Type 1 Effectiveness-Implementation randomized control trial (RCT) design, the investigators will test the effectiveness of a bundled behavioral activation and medication optimization in reducing symptoms of…
- Conditions
- Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy
- Trial name
- NCT05685511
- Testing
- Behavioral Activation, Medication Optimization, Usual care resources
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Washington University School of Medicine
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by…
- Conditions
- RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms
- Trial name
- AcceleRET-Lung (NCT04222972)
- Testing
- Pralsetinib, Carboplatin, Cisplatin
- Where
- 74 sites in Argentina, Australia and 20 more
- Volunteers
- 223 people
- Sponsor
- Hoffmann-La Roche
Dissection of Thoracic Aorta
Feasibility of Endovascular Repair of Ascending Aortic Pathologies
The purpose of this early feasibility study is to investigate the outcome of selected patients with ascending thoracic aortic pathologies including type A aortic dissection, who are suitable for endovascular repair with the…
- Trial name
- PS-IDE (NCT03322033)
- Testing
- Valiant PS-IDE Stent Graft
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Baylor Research Institute
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity
- Trial name
- NCT04021043
- Testing
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Pulmonary Function, Incentive Spirometry
Digital Incentive Spirometry Adherence
This single-arm proof-of-concept research study aims to assess the effect of a digital incentive spirometer (IS) device and a companion mobile-based app on incentive spirometry adherence in patients post-surgery.
- Conditions
- Pulmonary Function, Incentive Spirometry, Patient Adherence, Lung Resection
- Trial name
- NCT06629454
- Testing
- Adherence to digital incentive spirometer in the postop period after major chest surgery.
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Pennsylvania
Cancer, Thoracic Neoplasms
Improving Cancer On-treatment Symptom Management
Patient-reported outcome measures (PROMs) is an umbrella term that refers to any report on a health status measure that is reported directly by the patient, without the influence of clinicians or anyone else.
- Conditions
- Cancer, Thoracic Neoplasms, Gastrointestinal Cancer, Lung Cancer
- Trial name
- IMPROVE (NCT04589247)
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other Cancer, Gastrointestinal Cancer
Symptom Management Implementation of Patient Reported Outcomes in Oncology
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize…
- Conditions
- Other Cancer, Gastrointestinal Cancer, Thoracic Cancer, Gynecologic Cancer
- Trial name
- SIMPRO (NCT03850912)
- Testing
- Stakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview
- Where
- 6 sites in United States
- Volunteers
- 42,808 people
- Sponsor
- Dana-Farber Cancer Institute
Aortic Aneurysm, Thoracic, Chronic Type B Dissection
Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending TAA and Chronic Dissections
The purpose of the Feasibility study is to characterize the safety of the Valiant Mona LSA Thoracic Stent Graft System, including an assessment of the safety and effectiveness of the device acutely and at the 30 day visit in the…
- Trial name
- NCT02365467
- Testing
- Valiant Mona LSA Thoracic Stent Graft System
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medtronic Cardiovascular
Thoracic Surgery
Local Anesthetic as Single Shot Versus Catheter in Patients Undergoing Video Assisted Thoracoscopic Surgery
The purpose of this research is to compare a single shot long acting local anesthetic to catheter infusion of local anesthetic in patients undergoing video assisted thoracoscopic (VAT) surgery.
- Trial name
- NCT04559347
- Testing
- Liposomal Bupivacaine (EXPAREL®)/Bupivacaine, Ropivacaine (0.5% bolus followed by 0.2% infusion)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Poovendran Saththasivam
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche